This remained unchanged while on angiotensin-II with TnECHO on the day of initiation and after stable infusion dose showing stable markers of pulmonary vascular resistance and pulmonary hypertension in addition to no deterioration of heart function parameters or clinical worsening in terms of oxygenation or ventilation parameters. The gene discussed is AGT; the disease is pulmonary hypertension.